1-3 of 3
Hemant Patel
Close
Sort by
Journal Articles

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

Luis Fayad, Hemant Patel, PhD, Gregor Verhoef, Mitchell R. Smith, Peter W.M. Johnson, MD, FRCP, Myron S. Czuczman, MD, Bertrand Coiffier, Georg Hess, Eva Gine, Anjali Advani, MD, Fritz Offner, MD, Erik R. Vandendries, MD, PhD, Mark Shapiro, MD, PhD, FACP, Nam H. Dang, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 266.
https://doi.org/10.1182/blood.V112.11.266.266
Published: 2008
Journal Articles

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Luis Fayad, MD, Hemant Patel, PhD, Gregor Verhoef, MD, PhD, Myron Czuczman, MD, James Foran, MD, Eva Gine, MD, Ama Rohatiner, MD, Mitchell R. Smith, MD, Mark Shapiro, MD, PhD, Anjali Advani, MD
Journal: Blood
Blood (2006) 108 (11): 2711.
https://doi.org/10.1182/blood.V108.11.2711.2711
Published: 2006
Journal Articles

Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).

Anjali Advani, Eva Giné, Christian Gisselbrecht, Ama Rohatiner, Steven Rosen, Mitchell Smith, Joseph Boni, Chantal Lejeune, Hemant Patel
Journal: Blood
Blood (2005) 106 (11): 230.
https://doi.org/10.1182/blood.V106.11.230.230
Published: 2005